Isomorphic Labs

Isomorphic Labs is an AI-first drug design and development company founded in 2021 as a spin-out from Google DeepMind. Built on the Nobel Prize-winning AlphaFold system, the company is on a mission to transform drug discovery using artificial intelligence — with the ultimate ambition of one day solving all disease.

Led by founder and CEO Sir Demis Hassabis, Isomorphic has developed a unified AI drug design engine comprising foundational models capable of working across multiple therapeutic areas and drug modalities. Its breakthrough AlphaFold 3, released in May 2024 in collaboration with Google DeepMind, can predict the structure and interactions of all of life's molecules with unprecedented accuracy.

The company has established major research partnerships with pharmaceutical giants Eli Lilly and Novartis, and is developing its own internal drug pipeline focused on oncology and immunology. In March 2025, Isomorphic raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, bringing the company to the cusp of its first human clinical trials.

Isomorphic Labs is headquartered in London and has an office in Lausanne, Switzerland.